The ABN guidelines are suggesting that most high efficacy DMTs are treated the same. The MS Academy hosted a debate on 31 March 2020 to discuss whether ocrelizumab and cladribine should be treated in the same way as alemtuzumab in terms of risk of #COVID19.
Alemtuzumab = cladribine = ocrelizumab
If you have an hour on your hands the debate between ProfK and ProfB is here.
Apologises to ProfK for using the national stereo for the sake of levity